Open AccessCould Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept
Author(s) -
Georgia Anastasiou,
Erifili Hatziagelaki,
Evangelos Liberopoulos
Publication year - 2021
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/fjc.0000000000001011
Subject(s) - dapagliflozin , covid-19 , diabetes mellitus , medicine , comorbidity , epidemiology , intensive care medicine , disease , type 2 diabetes , endocrinology , virology , outbreak , infectious disease (medical specialty)
Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact of dapagliflozin on COVID-19 and its complications.